MRI In Acute Stroke: Promises and Pitfalls

April 12, 2022
MRI imagining is becoming more available in acute settings; understanding MRI in stroke is critical to staying ahead of the curve.
0 Comments

How Do You Operationalize the Use of the ASPECTS Score and Is It the Poor Man’s CTP?

April 5, 2022
The ASPECTS score has become more widespread in use with the increase in availability of endovascular therapy. This podcast is a must if you care for acute stroke patients. This is an absolute "must-know" topic for anyone who looks at head CT images in strokes.
0 Comments

Ataxia and Dystaxia: How To Examine and Discuss These Disabling Symptoms With Your Patients

March 29, 2022
Ataxia and dystaxia are often missed clinically. But they're important and potentially disabling. Listen to this podcast to learn more and help you identify these high-risk patients.
0 Comments

Posterior Circulation Horror Stories: How To Save the Day and Your Patient

March 22, 2022
Posterior circulation strokes are often devastating. The diagnostics are different and the treatments are evolving. If you care for stroke patients, this podcast is a must.
0 Comments

Confusion vs. Aphasia- So Important and So Challenging at Times!

March 15, 2022
Confusion isn't really a stroke symptom but aphasia clearly is. One is life threatening and the other can often be self limited and benign. Are you sure your neurological exam is up to the task?
0 Comments
RSS
135678910Last
Categories
More Entries

Sep 7

Why Is the Extended Window Controversial and What Happened With the FDA?

Haemin Go posted on 9/7/2021

Moderator: William A. Knight IV, MD, FACEP, FNCS
Other Participants: Stacie L. Demel, DO, PhD

The ECASS 3 trial was an RCT of IV-rtPA in the window of 3-4.5 hrs after onset of stroke symptoms. It was conducted in Europe. The European regulatory bodies have endorsed tPA for that window, but the FDA has not. Listen to two national experts in stroke discuss the trial and the meaning of the endorsement or lack thereof. This podcast is a must for acute stroke practitioners!

2 Comments
Tweet Share

2 comments on article "Why Is the Extended Window Controversial and What Happened With the FDA?"

Avatar image

Ken Milne

I watched the video on ECASS-III and you mentioned the controversy in this time window. However, there was no mention of Alper et al reanalysis in the BMJ_EBM that questioned the results? Can you comment? https://ebm.bmj.com/content/25/5/168


Avatar image

Ken Milne

Here was some of our feedback on Alper et al https://ebm.bmj.com/content/early/2020/08/10/bmjebm-2020-111517
Please login or register to post comments.
STAY CONNECTED
Let’s expand your stroke education network. Follow us on Twitter to get the latest updates about stroke education and stay up-to-date on hot topics in stroke care.
@stroke_journey
ABOUT THE STROKE JOURNEY
The Stroke Journey is an initiative developed by The National Stroke Education Center (NSEC) that strives to be the premier source of educational information for the diagnosis and treatment of stroke in the United States. NSEC extends the world-class educational expertise of the University of Cincinnati Department of Emergency Medicine and its partners via a variety of traditional and digital resources. NSEC and The Stroke Journey are dedicated to providing outstanding stroke education with timely material that mirrors the real-time changes in the medical education and stroke care landscape.
OUR PARTNERS
The Stroke Journey is a collaboration between the NSEC, EMCREG-International, and MedEd On The Go. Together we are committed to providing high-quality stroke education for healthcare professionals.
NSEC Sponsor Logo
EMREG Sponsor Logo
MedEd Sponsor Logo
Copyright 2024 The Stroke Journey | Privacy Policy | Terms of Use | Help & Support
Copyright 2024 The Stroke Journey
Privacy Policy | Terms of Use | Help & Support
Powered by MedEdOTG.com